LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SNDX
Syndax Pharmaceuticals, Inc.
There isn't enough reported data to score SNDX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SNDX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SNDX's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SNDX PE Valuation
SNDX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SNDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SNDX's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SNDX on earnings quality, reporting a profit while its opponent remains loss making.
SNDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.36 | +$1.24 |
| Q2 2026 | -$2.51 | +$1.37 |
| Q1 2026 | -$2.79 | +$1.06 |
| Q4 2025 | -$3.29 | +$0.43 |
| Q3 2025 | -$3.60 | +$0.05 |
| Q2 2025 | -$3.88 | -$0.48 |
| Q1 2025 | -$3.85 | -$0.61 |
| Q4 2024 | -$3.72 | -$0.74 |
SNDX is still losing money, but less than at its worst: $2.36 per share over the past year, against $3.88 at its worst in mid-2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SNDX on profitability, with a higher operating margin.
SNDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.3M | +82% |
| Q2 2026 | $72.8M | +92% |
| Q1 2026 | $64.9M | +224% |
| Q4 2025 | $68.7M | +795% |
| Q3 2025 | $45.9M | +267% |
| Q2 2025 | $38M | +985% |
| Q4 2021 | $126.6M | +33209% |
| Q3 2021 | $12.4M | +3165% |
SNDX has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -50% | +75 points |
| Q2 2026 | -55% | +128 points |
| Q1 2026 | -53% | +365 points |
| Q4 2025 | -91% | +1164 points |
| Q3 2025 | -125% | +591 points |
| Q2 2025 | -183% | +1938 points |
| Q1 2025 | -418% | N/A |
| Q4 2024 | -1255% | N/A |
SNDX's operating margin was −50% last quarter, up 75 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with SNDX at up 4.7%.
SNDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.3M | +$43.3M |
| Q2 2026 | -$30.3M | +$57.5M |
| Q1 2026 | -$50.3M | +$44.8M |
| Q3 2025 | -$70.5M | -$8.2M |
| Q2 2025 | -$87.8M | -$16.2M |
| Q1 2025 | -$95.2M | -$11.6M |
| Q3 2024 | -$62.3M | -$17.7M |
| Q2 2024 | -$71.6M | -$36.3M |
SNDX has burned cash in almost every quarter: −$178M over the past year, against −$303M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SNDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SNDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +799K shares |
| 1 year | +3.7% | +3.2M shares |
| 3 years | +29% | +19.9M shares |
| 5 years | +73% | +37.8M shares |
| Available history | +184% | +58.1M shares |
SNDX has 90M diluted shares, up 3.7% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SNDX Net Leverage
SNDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SNDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 5.3 | Oversold |
SNDX's weekly RSI is 26 (oversold) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SNDX PE vs Healthcare Sector
| Metric | SNDX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SNDX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SNDX on trend strength, trading above more of its moving averages.
SNDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 32% below |
| 20 week MA | $17.8 | 46% below |
| 50 week MA | $19.8 | 52% below |
| 100 week MA | $16.6 | 42% below |
| 200 week MA | $18.4 | 48% below |
SNDX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SNDX on returns for 2026, with the stronger performance.
SNDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.94 | $24.2 | +171% |
| 2021 | $24.2 | $22.5 | -7.1% |
| 2022 | $22.5 | $24.3 | +8.1% |
| 2023 | $24.3 | $21.6 | -11% |
| 2024 | $21.6 | $12.8 | -41% |
| 2025 | $12.8 | $21.3 | +67% |
| 2026 YTD | $21.3 | $9.54 | -55% |
SNDX's yearly returns have swung widely, from +171% in 2020 to −41% in 2024. It's down 55% so far in 2026.